<DOC>
	<DOC>NCT01585987</DOC>
	<brief_summary>The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and gastro-esophageal cancer.</brief_summary>
	<brief_title>An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Key Histologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the gastric and gastroesophageal junction Received firstline chemotherapy using fluoropyrimidine and platinum combination without disease progression Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Measurable disease by modified WHO criteria (unless complete response from previous chemotherapy) Key Known Human Epidermal growth factor Receptor2 (HER2) positive status Radiological evidence of brain metastases History of severe autoimmune or immune mediated disease requiring prolonged immunosuppressive treatment Inadequate hematologic, renal and hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>